LGND Financial Facts
Material sales: 4.22MResearch and development: 5.9M
See Full Income Statement
Inventory: 4.03M
Accounts payable: 2.76M
See Full Balance Sheet
Ligand Pharmaceuticals Inc. (LGND) Earnings
|
Expand Research on LGND
| Next EPS Date | 11/5/26 | EPS Growth Rate | -24.9% |
|---|---|---|---|
| Average EPS % Beat Rate | +26.4% | Revenue Growth Rate | -32.2% |
| Average % Move 1-Wk after EPS | +0.8% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/5/26  |
Q326 | N/A | $2.32 | N/A | N/A | $78.3M | = | N/A | N/A | ||
| 8/6/26 |
Q226 | $2.37 | $1.95 | +$0.42 | $83.7M | $62.93M | = |  | | Details | |
| 5/7/26 | Q126 | $1.63 | $1.84 | -$0.21 | $51.72M | $59.07M | = | | | Details | |
| 2/26/26 | Q425 | $2.02 | $1.49 | +$0.53 | $59.66M | $55.59M | = | | | Details | |
| 11/6/25 | Q325 | $3.09 | $1.93 | +$1.16 | $115.46M | $57.22M | = | | | Details | |
| 8/7/25 | Q225 | $1.60 | $1.43 | +$0.17 | $47.63M | $43.74M | = | | | Details | |
| 5/8/25 | Q125 | $1.33 | $1.22 | +$0.11 | $45.33M | $37.92M | = | | | Details | |
| 2/7/25 |
Q424 | N/A | $1.18 | N/A | N/A | $39.03M | = | N/A | N/A |
